Key Takeaways
- •"Purity" is undefined for a mixture. A single area-percent figure on a multi-component vial does not describe any component, and cannot be compared with a single-compound certificate.
- •The split is the product. "70mg" is a sum. Two vials with the same total and different ratios are different reagents, and one number cannot distinguish them.
- •A blend inherits the union of its components' liabilities. One storage temperature, one diluent, one shelf life, for compounds whose stability profiles do not agree.
- •The ratio is fixed at manufacture. Buying components separately keeps one degree of freedom per compound. Buying a blend spends all of them at once.
- •Degradation becomes unattributable. When a blend's chromatogram changes, you cannot tell which component moved without a per-component reference.
- •The correct use case is real: convenience and cost, when the ratio is already settled and the work does not depend on knowing it precisely.
Summary
Purity is a well-defined idea for a single peptide and an undefined one for a blend. On a four-component vial the largest chromatographic peak is not the product, it is a quarter of the product, and the other three peaks are not impurities either. A single area-percent figure on a mixture cannot be compared with a single-compound certificate, and most blend certificates carry one anyway.
What you are actually buying is the split, not the total. Seventy milligrams could be three roughly equal components or fifty milligrams of the cheapest one and ten each of the other two. Both satisfy a total-mass assay and they are different reagents. A disclosed split lets you compute a concentration per component, compare against buying them separately, and reproduce the ratio later. An undisclosed one lets you do none of that.
Three further costs follow. One vial gets one storage temperature and one diluent for compounds whose degradation liabilities do not agree. The ratio is fixed at manufacture, so every degree of freedom is spent at once. And when the chromatogram changes you cannot tell which component moved. None of which makes blends wrong: convenience and cost are real, and they are the right choice when the ratio is already settled.
A certificate for a single peptide reports a purity figure, and you know what it refers to: how much of the detectable material is the compound named on the label.
Now put four peptides in one vial and ask the same question. Purity of what? The largest peak is not the product, it is one quarter of the product. The other three peaks are not impurities, they are also the product. The arithmetic that makes a purity percentage meaningful has quietly stopped applying, and most blend certificates carry a number anyway.
Volta sells four blends, and since October 2026 all four state their components and their split in the product name. Two of them were sold until then under market nicknames and described as proprietary compositions, which is a reasonable example of why this article exists. The table at the end shows where each one stands.
This is not an argument that blends are bad. It is a statement of what you give up analytically when you buy one, so the decision is made deliberately. All material is supplied for laboratory research use only.
What a purity number means when the target is a mixture
Reversed-phase HPLC separates what is injected and reports each peak's share of the total detected area. For a single peptide, one peak dominates and its share is the purity.
For a blend, the chromatogram has as many main peaks as there are components, and three separate things get conflated:
| What you might mean by "99% pure" | Whether a blend certificate answers it |
|---|---|
| The largest peak is 99% of the area | Answers a question nobody asked. On a four-way blend the largest component may be a quarter of the mass |
| The four intended peaks together are 99% of the area | Meaningful, and this is usually what the number is. It says the vial is 99% peptide of some kind |
| Each component is individually 99% pure | Not answered at all, and this is what most readers assume |
The second reading is the useful one and it is much weaker than it looks. It confirms that the vial contains little foreign material. It says nothing about whether the four peptides are present in the intended proportions, whether any one of them is degraded, or whether a deletion sequence of one component is hiding under the peak of another.
And that summed figure is a harder standard to hit, not an easier one, because every component contributes its own impurities. A blend of four compounds each individually 99% pure cannot itself be more than about 99% pure, and any co-elution between one component's impurity and another component's main peak makes the number optimistic.
Co-elution, and why it matters more here
In a single-compound run, anything that co-elutes with the main peak inflates the purity figure. That risk exists for every peptide.
In a blend it multiplies. Four main peaks mean four retention windows where an impurity can hide, and the components themselves may not be well resolved from one another if their hydrophobicities are close. Where two components partly overlap, the integration boundary between them is drawn by software or by an analyst, and the split between the two areas becomes an estimate rather than a measurement.
That is the specific analytical cost: in a blend, the ratio between components is measured by the same operation that is least reliable when peaks are close together. A supplier reporting a component split from a chromatogram is reporting an integration, and integrations of partly-resolved peaks carry real uncertainty that is essentially never quoted.
The split is the whole product
"70mg" on a three-component vial and "80mg" on a four-component one are totals. A total constrains almost nothing.
Consider a three-component blend labelled 70mg. It could be roughly equal thirds. It could be 50mg of the cheapest component and 10mg each of the other two. Both are 70mg. Both would satisfy a total-mass assay. They are different reagents, and any result obtained with one does not transfer to the other.
This is why the disclosed-split blends are in a different category. BPC-157 + TB-500 10mg states 5+5. CJC-1295 No DAC + Ipamorelin 10mg states 5+5. With a stated split you can compute a concentration per component after reconstitution, compare price against buying the components separately, and reproduce the ratio later from single compounds if you need to. Without one you can do none of those things.
There is a commercial reason for undisclosed splits, and it is worth naming rather than pretending otherwise: a proprietary ratio is harder for a competitor to copy, and harder for a customer to replicate more cheaply from single vials. That is a legitimate business interest. It is also, unavoidably, a transfer of information away from the person doing the experiment.
In Stock Now
A batch-specific Certificate of Analysis is available for every vial below. Supplied for laboratory research use only.
GLP-3 RT 20mg
BPC-157 5mg
5mg
GLP-1 SM 10mg
BPC-157 + TB-500 10mg (5+5)
10mg
CJC-1295 No DAC + Ipamorelin 10mg (5+5)
10mg
GLP-3 RT 10mg
GHK-Cu 50mg
Tesamorelin 10mg
BPC-157 10mg
10mg
GLP-2 TZ 10mg
GHK-Cu + KPV + BPC-157 + TB-500 80mg (50+10+10+10)
80mg
KPV 10mg
HCG 5,000iu
HCG 10,000iu
Melanotan II 10mg
Ipamorelin 5mg
MOTS-C 10mg
TB-500 10mg
10mg
GHK-Cu 100mg
Epithalon 10mg
GHRP-2 5mg
5mg
GHRP-6 5mg
5mg
Cagrilintide 5mg
Sermorelin 10mg
GLP-1 SM 20mg
GLP-2 TZ 30mg
DSIP 10mg
SS-31 10mg
10mg
5-Amino-1MQ 10mg
5-Amino-1MQ 5mg
>99% HPLC purity standard. Read the Certificates of Analysis.
See the full Canadian catalogueOne vial, four stability profiles
Every peptide has its own degradation liabilities, driven by its sequence. Methionine and cysteine oxidise. Asparagine and glutamine deamidate. Aspartate isomerises. Copper complexes have their own chemistry entirely.
A single compound gets storage conditions chosen for its own liabilities. A blend gets one set of conditions for all of them, so the conditions are chosen for the most fragile component and the rest are merely tolerated, or they are chosen as a compromise and nothing is optimal.
The same applies down the line:
| Decision | Single compound | Blend |
|---|---|---|
| Storage temperature | Chosen for that sequence | One compromise across all components |
| Diluent and pH | Chosen for that sequence's solubility and stability | One compromise, and a pH good for a copper peptide is not automatically good for the others |
| Shelf life after reconstitution | Set by that compound | Set by whichever component fails first |
| Freeze-thaw tolerance | Known per compound | Governed by the least tolerant component |
| Interpreting a change | A purity drop points at one molecule | A purity drop points at the vial |
That last row is the one researchers underrate. When a single-compound vial degrades, the chromatogram tells you what happened. When a blend degrades, you see the summed area fall and the peak pattern shift, and attributing it requires per-component reference material you probably do not have.
The freeze-thaw calculator and the storage guide cover the handling side, and the batch comparison tool is built for holding two certificates side by side.
When a blend is the right call
All of the above is a cost, and costs are worth paying for benefits. Blends earn their place when:
- The ratio is already settled by prior work, and you want to stop re-deriving it.
- Convenience genuinely dominates, because handling one vial instead of four removes three chances to make a transfer error, and transfer error is a real source of variance.
- Cost per milligram is better than assembling the same components separately, which it frequently is.
- The work does not depend on attributing an effect to one component. Screening a combination as a unit is a legitimate design.
A blend is the wrong call when you need to vary one component independently, when a result has to be attributed to a specific molecule, or when the material feeds anything that will be published or compared against literature values for the individual compounds.
Volta's own blends, audited
Applying the article's own standard to our catalogue, since applying it to everyone else's would be cheap.
| Blend | Total | Components named | Split stated | What that means for you |
|---|---|---|---|---|
| BPC-157 + TB-500 | 10mg | Yes | Yes, 5+5 | Per-component concentration is computable. Comparable against buying both separately |
| CJC-1295 No DAC + Ipamorelin | 10mg | Yes | Yes, 5+5 | As above |
| GHK-Cu + BPC-157 + TB-500 | 70mg | Yes | Yes, 50+10+10 | Per-component concentration is computable from the stated split. No published certificate yet measures each component |
| GHK-Cu + KPV + BPC-157 + TB-500 | 80mg | Yes | Yes, 50+10+10+10 | The stated split is checkable: the certificate below measures each component of one lot separately |
The last two rows were sold until October 2026 under market nicknames and described as proprietary, while a calculator preset on the same site named their components. Both are now named by component and split, which is the arrangement this article argues for. The four-component vial also has a certificate that measures each component, below.
For the general problem of reading what a certificate does and does not establish, see identity is the test almost nobody runs and how to tell if a peptide supplier is legitimate. The quality page sets out our standard.
A worked example: what the four-component certificate actually lets you compute
The argument above is abstract until a real certificate is put against it, so here is the one blend on this site whose certificate does what the article asks for.
Lot VPKL80100 of GHK-Cu + KPV + BPC-157 + TB-500 80mg was analysed by SideChain Analytics (report COA-2026-SC-02802, 27 September 2026) by HPLC-MS/MS, and the certificate measures each component separately:
| Component | Mass | Chromatographic purity |
|---|---|---|
| GHK-Cu | 62.48 mg | 99.81% |
| KPV | 11.29 mg | 99.64% |
| TB-500 | 11.02 mg | 99.62% |
| BPC-157 | 10.72 mg | 99.59% |
That is the format this article is arguing for, and it is worth being precise about what it buys you:
- The split is stated, so per-component concentration after reconstitution is computable rather than guessed.
- Total net peptide content is 95.5 mg against an 80 mg label claim: a fill accuracy of 119.4%. A single blend purity figure would have hidden that entirely.
- There is no single purity figure for the vial, and that is correct. A blend composition report measures components, not mixtures. Where a figure is needed, 99.74% is the mass-weighted average of those four, arithmetic done here, not a laboratory finding, and no laboratory has reported a single purity for this blend.
- GHK-Cu is 65% of the net peptide and also the highest of the four figures. That is exactly the asymmetry the article describes: quoting the best component, or an unweighted mean, flatters the vial.
The full breakdown is in the measured composition article, and the certificate itself is linked from the product page and the certificate library.
Frequently Asked Questions
Can a blend have a meaningful purity figure?
Only if the certificate says what the figure covers. "The four intended components together account for 99% of the detected area" is meaningful and checkable. A bare "99%" on a multi-component vial does not identify what was measured, and readers reliably interpret it as a per-component claim, which it is not.
Why do suppliers not state the split?
Sometimes because the ratio is genuinely proprietary and disclosing it lets a competitor copy the product or lets a customer rebuild it more cheaply from single vials. That is a real commercial interest. It is still information the person running the experiment needed, and there is no version of the trade where the researcher comes out ahead.
Is a blend less pure than its components?
Not in the way that is usually meant. Where a single figure is quoted for a blend it is a mass-weighted average of the component purities, so it sits between the least pure and the most pure component rather than at or below the weakest one. The four-component certificate above is the worked example: components at 99.59, 99.62, 99.81 and 99.64 percent average 99.74 percent weighted by net peptide content, which is higher than three of the four. What is true is that the average flatters the vial whenever the largest component is also the purest, that no laboratory has reported a single purity for the mixture at all, and that every component contributes its own impurities to the total. A blend of components each at 99 percent sits at 99 percent, and below it only where an impurity from one component overlaps the peak of another.
Can I separate a blend back into its components?
Analytically, often yes: that is what the chromatogram does. Preparatively, at usable scale and purity, it is a purification project, not a bench step. Treat a blend as a one-way operation.
Does a blend cost more or less than buying the components separately?
Usually less per milligram, which is a genuine advantage. The comparison is only computable when the split is stated, though. Against an undisclosed ratio you are comparing a known quantity with an unknown one, and the cheaper number is not necessarily the better value. The cost calculator handles the per-milligram arithmetic when you have the inputs.
If a blend's purity drops over time, which component degraded?
You cannot tell from a summed figure. You need a chromatogram, retention times for each component from a reference run, and ideally reference material for each compound. This is the strongest practical argument for buying single compounds when the stability of the material is itself part of what you are studying.
